<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Respiratory syncytial virus infection: Treatment in infants and children
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Respiratory syncytial virus infection: Treatment in infants and children
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Respiratory syncytial virus infection: Treatment in infants and children
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Frederick E Barr, MD, MBA
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Barney S Graham, MD, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Morven S Edwards, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Diane Blake, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jan 09, 2024.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Respiratory syncytial virus (RSV) causes acute respiratory tract illness in persons of all ages. Almost all children are infected by two years of age, and reinfection is common [
         <a href="#rid1">
          1
         </a>
         ]. The clinical manifestations vary with age, health status, and whether the infection is primary or secondary.
        </p>
        <p>
         The treatment of RSV in infants, children, and adults will be discussed here. The discussion assumes that the patient's illness is severe enough to require hospital admission and/or to pursue an etiologic diagnosis since specific etiologic diagnosis is usually not sought in otherwise healthy patients with mild respiratory tract infections who are treated symptomatically as outpatients. (See
         <a class="medical medical_review" href="/z/d/html/5994.html" rel="external">
          "Respiratory syncytial virus infection: Clinical features and diagnosis in infants and children", section on 'Diagnosis'
         </a>
         .)
        </p>
        <p>
         Related topics include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5994.html" rel="external">
          "Respiratory syncytial virus infection: Clinical features and diagnosis in infants and children"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/15389.html" rel="external">
          "Respiratory syncytial virus infection: Prevention in infants and children"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/6018.html" rel="external">
          "Bronchiolitis in infants and children: Clinical features and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6020.html" rel="external">
          "Bronchiolitis in infants and children: Treatment, outcome, and prevention"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/16629.html" rel="external">
          "The common cold in children: Management and prevention"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6868.html" rel="external">
          "The common cold in adults: Treatment and prevention"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H265436168">
         <span class="h1">
          SUPPORTIVE CARE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Therapy for RSV infection of the lower respiratory tract is primarily supportive [
         <a href="#rid2">
          2,3
         </a>
         ]. Supportive care for patients with RSV lower respiratory tract infection includes frequent monitoring of clinical status and provision of fluid and respiratory support as necessary. The supportive care and inpatient treatment for bronchiolitis and pneumonia are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/6020.html" rel="external">
          "Bronchiolitis in infants and children: Treatment, outcome, and prevention", section on 'Moderate to severe bronchiolitis (inpatient management)'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6054.html" rel="external">
          "Pneumonia in children: Inpatient treatment", section on 'Supportive care'
         </a>
         .)
        </p>
        <p>
         Mechanical ventilation may be required in patients with severe respiratory symptoms and/or apnea due to RSV. The frequency of mechanical ventilation varies according to age and underlying health status from approximately 5 percent in infants hospitalized with RSV to up to 50 percent of adults with leukemia and myelosuppression [
         <a href="#rid4">
          4-8
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1140082124">
         <span class="h1">
          INDIVIDUALIZED MANAGEMENT
         </span>
        </p>
        <p class="headingAnchor" id="H1579785652">
         <span class="h2">
          RSV bronchiolitis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Infants and young children with RSV bronchiolitis are treated in the same manner as children with bronchiolitis caused by other pathogens. Supportive care is the mainstay of management. Management of bronchiolitis is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/6020.html" rel="external">
          "Bronchiolitis in infants and children: Treatment, outcome, and prevention"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4073444412">
         <span class="h2">
          RSV-associated bronchial reactivity
         </span>
         <span class="headingEndMark">
          —
         </span>
         Glucocorticoids and bronchodilators may be beneficial in the management of RSV-associated bronchial reactivity in older children, particularly those with asthma, in whom RSV-reinfection may have triggered an exacerbation. (See
         <a class="medical medical_review" href="/z/d/html/546.html" rel="external">
          "Treatment of recurrent virus-induced wheezing in young children"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5748.html" rel="external">
          "Acute asthma exacerbations in children younger than 12 years: Inpatient management", section on 'Elements of treatment'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/119093.html" rel="external">
          "Acute exacerbations of asthma in adults: Emergency department and inpatient management"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1047257234">
         <span class="h2">
          Immunocompromised patients
         </span>
         <span class="headingEndMark">
          —
         </span>
         Decisions regarding treatment of RSV infection in immunocompromised patients should be individualized. Treatment of RSV infection in immune-compromised patients has not been well studied and the optimal treatment is uncertain [
         <a href="#rid9">
          9,10
         </a>
         ].
        </p>
        <p>
         Interventions that have been associated with benefit (eg, reduced rates of progression from upper to LRTI, decreased mortality) in observational studies include single agent or combination therapy with
         <a class="drug drug_general" data-topicid="9860" href="/z/d/drug information/9860.html" rel="external">
          ribavirin
         </a>
         , intravenous
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          immune globulin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9849" href="/z/d/drug information/9849.html" rel="external">
          palivizumab
         </a>
         , and/or glucocorticoids [
         <a href="#rid9">
          9,10
         </a>
         ]. Although combination therapy with intravenous immune globulin and ribavirin or palivizumab has not been supported by a randomized trial, these combinations are sometimes used in severely ill immunocompromised patients.
        </p>
        <p>
         Data describing the efficacy of RSV treatment in adult hematopoietic cell transplant and lung transplant recipients is presented separately. (See
         <a class="medical medical_review" href="/z/d/html/142052.html" rel="external">
          "Respiratory syncytial virus infection in adults", section on 'Immunocompromised patients'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/13952.html" rel="external">
          "Viral infections following lung transplantation", section on 'Respiratory syncytial virus'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h1">
          PHARMACOTHERAPEUTIC AGENTS
         </span>
        </p>
        <p class="headingAnchor" id="H3129033651">
         <span class="h2">
          Ribavirin
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9860" href="/z/d/drug information/9860.html" rel="external">
          Ribavirin
         </a>
         is a nucleoside analog with good in vitro activity against RSV. Ribavirin is approved by the US Food and Drug Administration for the treatment of RSV infection.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Potential indications
         </strong>
         – Nebulized or oral
         <a class="drug drug_general" data-topicid="9860" href="/z/d/drug information/9860.html" rel="external">
          ribavirin
         </a>
         , alone or in combination with other interventions, may be warranted for the treatment of documented RSV infection in immunocompromised patients. (See
         <a class="local">
          'Immunocompromised patients'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/142052.html" rel="external">
          "Respiratory syncytial virus infection in adults", section on 'Immunocompromised patients'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_general" data-topicid="9860" href="/z/d/drug information/9860.html" rel="external">
          Ribavirin
         </a>
         is not routinely recommended for the treatment of RSV bronchiolitis in infants and children. (See
         <a class="local">
          'RSV bronchiolitis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Contraindications and precautions
         </strong>
         –
         <a class="drug drug_general" data-topicid="9860" href="/z/d/drug information/9860.html" rel="external">
          Ribavirin
         </a>
         is contraindicated in pregnant females, and a negative pregnancy test should precede its use in persons of child-bearing age.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Studies in rodents (rats, rabbits, hamsters) demonstrated teratogenicity and/or embryolethality [
         <a href="#rid11">
          11
         </a>
         ]. The risk in human pregnancy is uncertain due to the small number of reported exposures, but preliminary findings from a
         <a class="drug drug_general" data-topicid="9860" href="/z/d/drug information/9860.html" rel="external">
          ribavirin
         </a>
         pregnancy registry have not suggested human teratogenicity [
         <a href="#rid12">
          12
         </a>
         ]. Congenital anomalies occurred in 3 of 49 live births with direct maternal exposures and 3 of 69 live births following indirect exposure via the male sexual partner, with no consistent pattern of abnormality.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The prescribing information for oral
         <a class="drug drug_general" data-topicid="9860" href="/z/d/drug information/9860.html" rel="external">
          ribavirin
         </a>
         recommends that ribavirin be avoided in males whose partners are pregnant [
         <a href="#rid13">
          13
         </a>
         ]. Given the long half-life of ribavirin, it is also recommended that female patients who receive ribavirin avoid pregnancy for nine months after completion of treatment and that the female partners of males who receive ribavirin avoid pregnancy for six months after completion of treatment.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_general" data-topicid="9860" href="/z/d/drug information/9860.html" rel="external">
          Ribavirin
         </a>
         has been associated with bronchoconstriction and should be used in caution in patients with asthma or chronic obstructive pulmonary disease [
         <a href="#rid14">
          14
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adverse
         </strong>
         <strong>
          effects
         </strong>
         – Adverse effects of
         <a class="drug drug_general" data-topicid="9860" href="/z/d/drug information/9860.html" rel="external">
          ribavirin
         </a>
         include hemolytic anemia, leukopenia, cough, dyspnea, bronchospasm, deterioration in pulmonary function, rash, conjunctival irritation, and neuropsychologic symptoms [
         <a href="#rid9">
          9,14-16
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Adverse effects related to occupational exposure to
         <a class="drug drug_general" data-topicid="9860" href="/z/d/drug information/9860.html" rel="external">
          ribavirin
         </a>
         have not been reported. However, the National Institute of Occupational Safety and Health has published recommendations to reduce the ambient air concentrations of ribavirin and limit occupational exposure to hospital personnel [
         <a href="#rid17">
          17
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3011326394">
         <span class="h2">
          Immune globulin
         </span>
         <span class="headingEndMark">
          —
         </span>
         Intravenous
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          immune globulin
         </a>
         (IVIG) alone or in combination with other agents (eg,
         <a class="drug drug_general" data-topicid="9860" href="/z/d/drug information/9860.html" rel="external">
          ribavirin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9849" href="/z/d/drug information/9849.html" rel="external">
          palivizumab
         </a>
         ) has been tried in the treatment of RSV infection.
        </p>
        <p>
         Although it is no longer available,
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         with high neutralizing activity against RSV (RSV-IVIG) was shown to prevent RSV replication in lung tissues, reduce viral loads in pulmonary tissues, and prevent subsequent development of illness in immunocompetent and immunocompromised animal models [
         <a href="#rid18">
          18,19
         </a>
         ].
        </p>
        <p>
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         may be warranted for the treatment of documented RSV infection in immunocompromised patients. (See
         <a class="local">
          'Immunocompromised patients'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/142052.html" rel="external">
          "Respiratory syncytial virus infection in adults", section on 'Immunocompromised patients'
         </a>
         .)
        </p>
        <p>
         The clinical use and adverse effects of
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4431.html" rel="external">
          "Overview of intravenous immune globulin (IVIG) therapy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3944.html" rel="external">
          "Intravenous immune globulin: Adverse effects"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1532219823">
         <span class="h2">
          Monoclonal antibodies
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Palivizumab
         </strong>
         –
         <a class="drug drug_general" data-topicid="9849" href="/z/d/drug information/9849.html" rel="external">
          Palivizumab
         </a>
         is an RSV-specific humanized monoclonal antibody. The typical intravenous dose (15 mg/kg) has a serum half-life of approximately 20 days in adult hematopoietic cell transplant (HCT) recipients without RSV and 11 days in HCT recipients with RSV infection [
         <a href="#rid20">
          20
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Whether specific populations of immunocompromised patients benefit from
         <a class="drug drug_general" data-topicid="9849" href="/z/d/drug information/9849.html" rel="external">
          palivizumab
         </a>
         therapy for RSV infection is uncertain. It has not been evaluated in randomized trials. In observational studies, palivizumab has not been definitively associated with reduced severity of RSV infection or mortality, although it appears to be well tolerated [
         <a href="#rid20">
          20-22
         </a>
         ]. Adverse reactions to palivizumab include fever, rash, and antibody development.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The role of
         <a class="drug drug_general" data-topicid="9849" href="/z/d/drug information/9849.html" rel="external">
          palivizumab
         </a>
         in the prevention of RSV infections, is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/15389.html" rel="external">
          "Respiratory syncytial virus infection: Prevention in infants and children", section on 'Immunoprophylaxis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Nirsevimab
         </strong>
         –
         <a class="drug drug_general" data-topicid="141488" href="/z/d/drug information/141488.html" rel="external">
          Nirsevimab
         </a>
         is a monoclonal antibody that targets the prefusion conformation of the RSV F glycoprotein. It has a long half-life and potent neutralizing activity. Nirsevimab has not been studied in the treatment of patients with documented RSV infection. It is used for prevention of RSV in infancy, as discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/15389.html" rel="external">
          "Respiratory syncytial virus infection: Prevention in infants and children", section on 'Immunoprophylaxis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2511168272">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/112263.html" rel="external">
          "Society guideline links: Bronchiolitis in infants and children"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H29">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or email these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient education" and the keyword[s] of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topic (see
         <a class="medical medical_patient" href="/z/d/html/1213.html" rel="external">
          "Patient education: Bronchiolitis and RSV in infants and children (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H30">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Supportive care
         </strong>
         – Therapy for respiratory syncytial virus (RSV) infection of the lower respiratory tract is primarily supportive. Supportive care includes frequent monitoring of clinical status and provision of fluid and respiratory support as necessary. (See
         <a class="local">
          'Supportive care'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Children with RSV bronchiolitis are treated in the same manner as children with bronchiolitis caused by other pathogens. Supportive care is the mainstay of management. Treatment of bronchiolitis is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/6020.html" rel="external">
          "Bronchiolitis in infants and children: Treatment, outcome, and prevention"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Glucocorticoids and bronchodilators may be beneficial in the management of RSV-associated bronchial reactivity in older children and adults. (See
         <a class="local">
          'RSV-associated bronchial reactivity'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment of immunocompromised patients
         </strong>
         – Decisions regarding treatment of RSV infection in immunocompromised patients should be individualized. The optimal treatment is uncertain. Interventions that have been associated with reduced rates of progression from upper to lower respiratory tract infection or decreased mortality in observational studies include single agent or combination therapy with
         <a class="drug drug_general" data-topicid="9860" href="/z/d/drug information/9860.html" rel="external">
          ribavirin
         </a>
         , intravenous
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          immune globulin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9849" href="/z/d/drug information/9849.html" rel="external">
          palivizumab
         </a>
         , and/or glucocorticoids. (See
         <a class="local">
          'Immunocompromised patients'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/142052.html" rel="external">
          "Respiratory syncytial virus infection in adults", section on 'Immunocompromised patients'
         </a>
         .)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Committee on Infectious Diseases. From the American Academy of Pediatrics: Policy statements--Modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections. Pediatrics 2009; 124:1694.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jorquera PA, Tripp RA. Respiratory syncytial virus: prospects for new and emerging therapeutics. Expert Rev Respir Med 2017; 11:609.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kodama F, Nace DA, Jump RLP. Respiratory Syncytial Virus and Other Noninfluenza Respiratory Viruses in Older Adults. Infect Dis Clin North Am 2017; 31:767.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wald TG, Miller BA, Shult P, et al. Can respiratory syncytial virus and influenza A be distinguished clinically in institutionalized older persons? J Am Geriatr Soc 1995; 43:170.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Henderson FW, Collier AM, Clyde WA Jr, Denny FW. Respiratory-syncytial-virus infections, reinfections and immunity. A prospective, longitudinal study in young children. N Engl J Med 1979; 300:530.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Whimbey E, Couch RB, Englund JA, et al. Respiratory syncytial virus pneumonia in hospitalized adult patients with leukemia. Clin Infect Dis 1995; 21:376.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Seo S, Campbell AP, Xie H, et al. Outcome of respiratory syncytial virus lower respiratory tract disease in hematopoietic cell transplant recipients receiving aerosolized ribavirin: significance of stem cell source and oxygen requirement. Biol Blood Marrow Transplant 2013; 19:589.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Renaud C, Xie H, Seo S, et al. Mortality rates of human metapneumovirus and respiratory syncytial virus lower respiratory tract infections in hematopoietic cell transplantation recipients. Biol Blood Marrow Transplant 2013; 19:1220.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hirsch HH, Martino R, Ward KN, et al. Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis and treatment of human respiratory syncytial virus, parainfluenza virus, metapneumovirus, rhinovirus, and coronavirus. Clin Infect Dis 2013; 56:258.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beaird OE, Freifeld A, Ison MG, et al. Current practices for treatment of respiratory syncytial virus and other non-influenza respiratory viruses in high-risk patient populations: a survey of institutions in the Midwestern Respiratory Virus Collaborative. Transpl Infect Dis 2016; 18:210.
          </a>
         </li>
         <li class="breakAll">
          Reprotox. Ribavirin. www.reprotox.org/Members/AgentDetail.aspx?a=1334 (Accessed on December 19, 2013).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roberts SS, Miller RK, Jones JK, et al. The Ribavirin Pregnancy Registry: Findings after 5 years of enrollment, 2003-2009. Birth Defects Res A Clin Mol Teratol 2010; 88:551.
          </a>
         </li>
         <li class="breakAll">
          Rebetol (ribavirin) capsules and oral solution [package insert]. Whitehouse Station, NJ: Merck and Co, Inc; 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020903s057,021546s013lbl.pdf (Accessed on March 21, 2022).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shah JN, Chemaly RF. Management of RSV infections in adult recipients of hematopoietic stem cell transplantation. Blood 2011; 117:2755.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Krilov LR. Safety issues related to the administration of ribavirin. Pediatr Infect Dis J 2002; 21:479.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Manuel O, Estabrook M, American Society of Transplantation Infectious Diseases Community of Practice. RNA respiratory viral infections in solid organ transplant recipients: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant 2019; 33:e13511.
          </a>
         </li>
         <li class="breakAll">
          Hospital investigations: Health Hazards. In: OSHA Technical Manual (OTM). US Department of Labor; Occupational Safety and Health Administration, Washington, DC 1999.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Graham BS, Davis TH, Tang YW, Gruber WC. Immunoprophylaxis and immunotherapy of respiratory syncytial virus-infected mice with respiratory syncytial virus-specific immune serum. Pediatr Res 1993; 34:167.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ottolini MG, Porter DD, Hemming VG, et al. Effectiveness of RSVIG prophylaxis and therapy of respiratory syncytial virus in an immunosuppressed animal model. Bone Marrow Transplant 1999; 24:41.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boeckh M, Berrey MM, Bowden RA, et al. Phase 1 evaluation of the respiratory syncytial virus-specific monoclonal antibody palivizumab in recipients of hematopoietic stem cell transplants. J Infect Dis 2001; 184:350.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Fontbrune FS, Robin M, Porcher R, et al. Palivizumab treatment of respiratory syncytial virus infection after allogeneic hematopoietic stem cell transplantation. Clin Infect Dis 2007; 45:1019.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Permpalung N, Mahoney MV, McCoy C, et al. Clinical characteristics and treatment outcomes among respiratory syncytial virus (RSV)-infected hematologic malignancy and hematopoietic stem cell transplant recipients receiving palivizumab. Leuk Lymphoma 2019; 60:85.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 6001 Version 39.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19736258" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : From the American Academy of Pediatrics: Policy statements--Modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28574729" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Respiratory syncytial virus: prospects for new and emerging therapeutics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29079159" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Respiratory Syncytial Virus and Other Noninfluenza Respiratory Viruses in Older Adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7836643" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Can respiratory syncytial virus and influenza A be distinguished clinically in institutionalized older persons?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/763253" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Respiratory-syncytial-virus infections, reinfections and immunity. A prospective, longitudinal study in young children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8562747" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Respiratory syncytial virus pneumonia in hospitalized adult patients with leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23298855" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Outcome of respiratory syncytial virus lower respiratory tract disease in hematopoietic cell transplant recipients receiving aerosolized ribavirin: significance of stem cell source and oxygen requirement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23680472" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Mortality rates of human metapneumovirus and respiratory syncytial virus lower respiratory tract infections in hematopoietic cell transplantation recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23024295" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis and treatment of human respiratory syncytial virus, parainfluenza virus, metapneumovirus, rhinovirus, and coronavirus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26923867" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Current practices for treatment of respiratory syncytial virus and other non-influenza respiratory viruses in high-risk patient populations: a survey of institutions in the Midwestern Respiratory Virus Collaborative.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26923867" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Current practices for treatment of respiratory syncytial virus and other non-influenza respiratory viruses in high-risk patient populations: a survey of institutions in the Midwestern Respiratory Virus Collaborative.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20564430" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : The Ribavirin Pregnancy Registry: Findings after 5 years of enrollment, 2003-2009.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20564430" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : The Ribavirin Pregnancy Registry: Findings after 5 years of enrollment, 2003-2009.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21139081" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Management of RSV infections in adult recipients of hematopoietic stem cell transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12150196" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Safety issues related to the administration of ribavirin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30817023" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : RNA respiratory viral infections in solid organ transplant recipients: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30817023" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : RNA respiratory viral infections in solid organ transplant recipients: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8233720" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Immunoprophylaxis and immunotherapy of respiratory syncytial virus-infected mice with respiratory syncytial virus-specific immune serum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10435733" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Effectiveness of RSVIG prophylaxis and therapy of respiratory syncytial virus in an immunosuppressed animal model.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11443562" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Phase 1 evaluation of the respiratory syncytial virus-specific monoclonal antibody palivizumab in recipients of hematopoietic stem cell transplants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17879919" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Palivizumab treatment of respiratory syncytial virus infection after allogeneic hematopoietic stem cell transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29947555" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Clinical characteristics and treatment outcomes among respiratory syncytial virus (RSV)-infected hematologic malignancy and hematopoietic stem cell transplant recipients receiving palivizumab.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
